2027 Legislative Session Dates
image/svg+xml Skip to main content
Search image/svg+xml

Key Takeaways:

  • FDA's 2027 budget request seeks authority to deem a prescription drug misbranded if its direct-to-consumer ad lacks fair balance and creates a misleading impression about FDA approval, labeled use, or efficacy. This is part of broader FDA drug advertising rules under consideration.
  • FDA's proposed misbranded DTC ads standard builds on a 1969 regulation that already requires broadcast drug ads to present a clear, conspicuous, and neutral disclosure of risks alongside benefit information.
  • The FDA has also proposed eliminating the "adequate provision" standard, which would require broadcast ads to include all relevant risk and safety information within the ad itself rather than directing viewers elsewhere for it.
  • Sens. Durbin and Marshall introduced the Protecting Patients from Deceptive Drug Ads Act, which would require telehealth providers to include summary information in prescription drug ads.
  • Drug companies lobbying Congress on these issues need to understand the Lobbying Disclosure Act requirements, including the 20 percent time threshold, the $16,000 quarterly spending threshold, and the quarterly and semiannual reporting obligations that follow registration.

In its 2027 budget request, the Food and Drug Administration (FDA) requests authority to designate prescription drugs as "misbranded" if their direct-to-consumer (DTC) advertisements lack "fair balance." This legislative proposal would specifically deem a drug misbranded under the Federal Food, Drug, and Cosmetic (FD&C) Act if its DTC ad "lacks fair balance and creates a misleading impression regarding FDA approval, the scope of the FDA-approved indication(s) and the limitations of use, or the drug's efficacy and benefits."

What do prescription drug companies - the groups subject to this proposal - need to understand when lobbying Congress? Below are the registration and reporting requirements for employers of federal lobbyists, as well as recent agency activity on prescription drug advertising.

Regulatory Actions on Prescription Drug Advertising

Enacted in 1938 after a mass poisoning killed over 100 people, the FD&C Act authorizes the FDA to regulate the safety of cosmetics, food, medical devices, and pharmaceutical drugs. In 1969, the FDA adopted a regulation under the FD&C Act requiring prescription drug broadcast ads to disclose the risks of advertised drugs in a "clear, conspicuous, and neutral manner." This regulation also requires drug ads to "present a fair balance" between information about risks and information about effectiveness; this means an ad with detailed information on effectiveness but limited information on side effects would lack fair balance. The amount of time or space needed to present drug information will, of course, depend on a drug's risks and the manner in which benefits and risks are presented.

Despite the fair balance standard, the FDA under the Trump Administration has actively sought to curb misleading drug ads. Last September, the agency sent thousands of cease-and-desist letters to pharmaceutical companies over ads it deemed "misleading" and "deceptive." The FDA also proposed eliminating the "adequate provision" standard, which allows broadcast ads to direct consumers to print, website, or telephone ads for full risk information. Included within the 2026 Regulatory Plan and Unified Agenda (with a target publication date of December 2026), this proposed rule would require broadcast ads to disclose "all relevant risk and safety information to consumers within the confines of the ad itself." Industry experts have described this new disclosure requirement as a de facto broadcast ban, since drug ads are typically 30 seconds or one minute long.

Congress has also expressed interest in curtailing deceptive drug ads; last year, Sens. Durbin (D-IL) and Marshall (R-KS) introduced the Protecting Patients from Deceptive Drug Ads Act (S. 652), which would require telehealth providers to include summary information in prescription drug ads. Additionally, a recent analysis in the Journal of Pharmaceutical Health Services Research found that only 33 percent of drug industry social media posts mention potential harms of drugs (while 100 percent of posts highlight their benefits).

Defining Key Terms

Fair Balance (in Prescription Drug Advertising)

"Fair balance" is a regulatory standard requiring prescription drug advertisements to present information about a drug's risks and benefits in a balanced, clear, and neutral manner. This means that ads must not emphasize benefits while minimizing or omitting risks, ensuring consumers receive an accurate impression of the drug's safety and effectiveness.

Adequate Provision Standard

The "adequate provision" standard allows broadcast prescription drug ads to direct consumers to print, website, or telephone sources for complete risk information, rather than including all risk details in the ad itself. The FDA has proposed eliminating this standard, which would require all relevant risk and safety information to be disclosed within the broadcast ad.

Lobbying Disclosure Act Registration Triggers

What do drug companies need to know if their lobbyists contact the federal government on FDA's proposed fair balance policy? Under the Lobbying Disclosure Act (LDA), employers must register lobbyists if they initiate a "lobbying contact" with a member of Congress, congressional staff member, or a covered executive branch official (e.g., a Cabinet official or individual in a policy-making position). The LDA defines "lobbying contact" as an oral or written communication with a covered federal official through which a person seeks to influence federal legislation or federal government action or policy. Certain communications are excepted from this classification, including:

  • Speeches and other mass communications,
  • Communications made on behalf of a government of a foreign country or foreign political party and disclosed under the Foreign Agents Registration Act (FARA),
  • Administrative inquiries (e.g., meeting requests) provided the inquiry does not attempt to influence a covered official,
  • Communications made in the course of participating in an advisory committee subject to the Federal Advisory Committee Act,
  • Information provided in writing to an oral or written request by a covered official for specific information,
  • Communications made in response to a notice in the Federal Register (notice and comment rule-making), or similar publications soliciting communications from the public and directed to the official designated in the notice to receive these communications, and
  • Testimony provided before a congressional committee, subcommittee, or task force.

Additionally, registration is required for lobbyists who spend or anticipate spending at least 20 percent of their time during a three-month period on "lobbying activities," defined as the entire time spent preparing for lobbying contacts. Employers must also register under the LDA if they spend or expect to spend more than $16,000 in a calendar quarter on federal lobbying activities, which includes employee compensation and payments to lobbying firms. Registration must be made within 45 days after all of the above prerequisites are satisfied. Lastly, registrations are for the company employing the lobbyist; if an individual lobbyist meets the two contacts and 20 percent of time thresholds, they will be listed on the employer's quarterly report. There is no separate lobbyist registration for the federal government.

Quarterly and Semiannual Reporting Obligations

Once registered, employers must file quarterly lobbying reports listing all expenses related to lobbying activities by their lobbyists and non-lobbyist employees, as well as their registered lobbyists and any entities that qualify as "affiliates" or foreign parents. Additionally, registrants and each of their in-house lobbyists must file semi-annual political contribution reports.

As FDA and congressional scrutiny of prescription drug advertising continues, pharmaceutical companies should monitor regulatory developments and consider how proposed changes could affect their advertising practices and compliance obligations. Companies seeking to influence federal policy should also ensure they understand their LDA obligations, including registration thresholds, quarterly lobbying disclosures, and semiannual political contribution reporting. Staying ahead of policy developments and lobbying compliance requirements can help companies engage effectively with policymakers while avoiding unnecessary reporting violations.

Need Compliance Help? Get In Touch!

Keeping up with rules, deadlines, and often confusing requirements is a daunting prospect for teams of all sizes. Let us manage your federal, state, and local registration and reporting responsibilities, or manage your Campaign Finance program. Read more about our Compliance Services here, or get in touch here.

Frequently Asked Questions

What does the FDA's 2027 budget request propose regarding direct-to-consumer drug advertisements?

The FDA's 2027 budget request seeks authority to designate prescription drugs as "misbranded" under the FD&C Act if their direct-to-consumer advertisements lack "fair balance." Specifically, a drug would be deemed misbranded if its DTC ad "lacks fair balance and creates a misleading impression regarding FDA approval, the scope of the FDA-approved indication(s) and the limitations of use, or the drug's efficacy and benefits."

What is the "adequate provision" standard, and what has the FDA proposed doing with it?

The "adequate provision" standard currently allows broadcast drug ads to direct consumers to print, website, or telephone ads for full risk information. The FDA has proposed eliminating this standard, which would instead require broadcast ads to disclose all relevant risk and safety information within the confines of the ad itself. Industry experts have described this proposed requirement as a de facto broadcast ban, since drug ads are typically 30 seconds or one minute long.

When does a pharmaceutical company need to register under the Lobbying Disclosure Act?

A pharmaceutical company must register under the LDA if it employs a lobbyist who meets the lobbying contacts and 20 percent of time thresholds, or if the company spends or expects to spend more than $16,000 in a calendar quarter on federal lobbying activities. Registration must be completed within 45 days after all applicable prerequisites are satisfied.

What are the ongoing reporting obligations for a pharmaceutical company registered under the Lobbying Disclosure Act?

Once registered, employers must file quarterly lobbying reports listing all expenses related to lobbying activities by their lobbyists and non-lobbyist employees, as well as their registered lobbyists and any entities that qualify as affiliates or foreign parents. Additionally, registrants and each of their in-house lobbyists must file semi-annual political contribution reports.

What does S. 652, the Protecting Patients from Deceptive Drug Ads Act, require?

S. 652, introduced by Sens. Durbin and Marshall, would require telehealth providers to include summary information in prescription drug advertisements..